The latest price target for Protara Therapeutics (NASDAQ:TARA) was reported by Oppenheimer on August 12, 2024. The analyst firm set a price target for $25.00 expecting TARA to rise to within 12 months (a possible 1181.72% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Protara Therapeutics (NASDAQ:TARA) was provided by Oppenheimer, and Protara Therapeutics maintained their outperform rating.

There is no last upgrade for Protara Therapeutics

There is no last downgrade for Protara Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protara Therapeutics was filed on August 12, 2024 so you should expect the next rating to be made available sometime around August 12, 2025.

While ratings are subjective and will change, the latest Protara Therapeutics (TARA) rating was a maintained with a price target of $30.00 to $25.00. The current price Protara Therapeutics (TARA) is trading at is $1.95, which is out of the analyst’s predicted range.